Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Mott Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Thematic growth strategy underperformed in volatile Q1 marked by healthcare earnings disappointments and oil price surge from geopolitical tensions. Manager maintains conviction in biotechnology innovation while tactically adjusting energy exposure."
Mott Capital's Thematic Growth strategy declined 10.88% in Q1 2026 versus the S&P 500's 4.33% decline, driven primarily by healthcare disappointments from Boston Scientific, UnitedHealth, and Grail earnings in February. The quarter was marked by unexpected geopolitical developments as U.S.-Iran engagement led to Strait of Hormuz closure, sending WTI oil above $100 per barrel. The manager exited Boston Scientific after weak results and trimmed Amazon following strong gains, using proceeds to initiate a position in Intuit at attractive valuations. Despite Grail's cancer screening test missing its primary endpoint for early-stage detection, the manager maintains conviction in the underlying technology. Looking forward, oil volatility and narrow market leadership concentrated in mega-caps create challenging conditions. The key uncertainty is whether rising oil prices and reaccelerating inflation will force central banks to shift from easing to tightening, or trigger recession through reduced global output. Portfolio positioning reflects selective opportunities while managing heightened volatility.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
The manager displays moderate conviction at 0.65. While the strategy is concentrated with 10–20 positions, the manager acted decisively to exit Boston Scientific and prune Occidental, while retaining strong conviction in Grail's technology.
Growth Outlook
The manager rates the outlook at 0.25, indicating caution due to reaccelerating inflation, geopolitical conflicts, and rising oil prices that could trigger a central bank tightening cycle or recession.
Risk Appetite
The manager maintains a balanced risk profile at 0.50, trimming high-fliers like Amazon and Occidental to lock in gains and manage taxes, while redeploying proceeds into a new technology position in Intuit.
Capital Deployment
Capital deployment is neutral-cautious at 0.45. The manager recycled proceeds from exiting Boston Scientific and trimming Amazon/Occidental, alongside some existing cash, to buy Intuit.
Forward Guidance
The manager displays a neutral bias at 0.50, planning future reshuffling of the portfolio to navigate ongoing market volatility, but not showing aggressive buying or selling signals.
Language Signal
The language is slightly bearish at 0.35, dominated by words describing quarterly underperformance, disappointing earnings, rising inflation risks, and geopolitical conflicts.
Perceived Risk
Perceived risk is elevated at 0.75, driven by geopolitical tensions in the Strait of Hormuz, commodity price volatility, and the threat of reaccelerating inflation causing a recession.
Opportunity Density
Opportunity density is scored at 0.45. The manager notes narrow market leadership concentrated in mega-cap companies but was able to find selective value in Intuit following its decline.
Time Horizon
The strategy possesses a multi-year horizon scored at 0.70, focusing on long-term thematic trends like AI and biotechnology, although near-term volatility has forced some tactical adjustments.
